Medical News Today -- Use of the HIV antiretroviral treatment raltegravir, in combination with optimum background therapy, is a safe and effective alternative to conventional combination treatment using efavirenz in patients yet to start antiretroviral treatment. Furthermore, the raltegravir regimen is faster acting and causes fewer adverse events than the efavirenz regimen. These are the conclusions of an Article published Online First and in an upcoming edition of The Lancet, written by Dr Jeffrey L Lennox, Emory University School of Medicine, Atlanta, GA, USA, and colleagues.
